Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

Background Progress in characterising the humoral immune response to Severe Acute
Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist …

Aims To estimate the association of smoking status with rates of (i) infection,(ii)
hospitalization,(iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging
infectious diseases; its efficacy was later associated with the evidence that polyclonal …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently causing a
global pandemic. The antigen specificity of the antibody response mounted against this …

Background Convalescent plasma may reduce mortality in patients with viral respiratory
diseases, and is being investigated as a potential therapy for coronavirus disease 2019 …

Introduction The coronavirus disease 2019 (COVID-19) pandemic has spread globally.
Therapeutic options including antivirals, anti-inflammatory compounds, and vaccines are still …

Background: The role of venovenous extracorporeal membrane oxygenation (VV ECMO) in
patients with COVID-19-induced acute respiratory distress syndrome (ARDS) still remains …

Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …